Published in Obesity and Diabetes Week, August 22nd, 2005
Total annual market sales for Glimepiride were $336.6 million (+22.4%) (IMS - MAT: March 2005).
Glimepiride is indicated as an adjunct to diet and exercise, to lower the blood glucose in patients with noninsulin-dependent (type II) diabetes mellitus (NIDDM) whose hyperglycemia cannot be controlled by diet and exercise alone.
The product may be used concomitantly with Metformin when diet, exercise, and Glimepiride or...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.